Today we look at how advanced therapeutic modalities (ATMs) are revolutionizing drug discovery, development and manufacturing, presenting both unparalleled opportunities and new challenges for businesses.

Drawing from their knowledge, our experts Alex Vadas, Adam Siebert and Jeff Holder unpack how new drug therapies such as engineered cell therapies, gene therapies and nucleic acid therapies are revolutionizing patient care and treatment options. They highlight the need for innovative business strategies to navigate complex manufacturing processes and supply chain logistics, the role of regulatory engagement, and the influence of artificial intelligence (AI) and machine learning in the realm of drug discovery.

Key points/topics covered:

• The transformative impact of new drug therapies on life sciences, requiring adaptations in business strategies
• The complexity of manufacturing for ATMs and its effect on the commercial viability of new treatments
• The importance of regulatory engagement in streamlining the drug development timeline for advanced therapies
• The intersection of AI and machine learning in expediting drug discovery for cell and gene therapies
• Manufacturing efficiency and supply chain consistency as a key differentiator in the outcomes and success rates of ATMs
  Interested in learning more? Read our Harvard Business Review article, A New Generation of Drug Therapies Requires New Business Strategies.

Connect with our experts on LinkedIn:
Alex Vadas, Managing Director, L.E.K. Consulting: https://www.linkedin.com/in/alexvadas/
Adam Siebert, Managing Director, L.E.K. Consulting: https://www.linkedin.com/in/adam-siebert-8772b327/
Jeff Holder, Managing Director, L.E.K. Consulting: https://www.linkedin.com/in/jeff-holder-ph-d-7a391087/

Visit L.E.K. Consulting at https://www.lek.com/

In today’s episode, we will focus on the influential trends and investment priorities shaping the specialty chemicals industry. Our subject matter experts will discuss the surge in innovation, digital transformation, and sustainability in the chemicals sector and highlight the strategic responses to recent industry challenges.

Key points/topics covered:

• Current investment trends and strategic priorities, such as innovation in alternative feedstocks and diversification in the specialty chemicals industry
• The implementation and impact of digital strategies, including operational efficiency and business growth, within chemical companies
• The significance of sustainability goals and consumer demand for sustainable products, which are driving specialty chemical manufacturers to innovate
• Actions taken by the chemical industry to promote more sustainable raw materials and leverage biosimilar opportunities and recycling
• Future directions for the chemicals industry, including addressing supply chain optimization and operational efficiency

To provide insights on these topics, you will hear from L.E.K. Consulting Managing Directors Carol Wingard, Peter Walter, Morgan Callahan and Amanda Davis Winters.

Interested in learning more? Read our Article, Key Issue Insights Into the Future of Specialty Chemicals.

Connect with our experts on LinkedIn:
Carol Wingard: https://www.linkedin.com/in/carolwingardlek/
Peter Walter: https://www.linkedin.com/in/peterwalterlek/
Morgan Callahan: https://www.linkedin.com/in/morganjcallahan/
Amanda Davis Winters: https://www.linkedin.com/in/adaviswinters/

Visit L.E.K. Consulting at https://www.lek.com/

In this episode of “Insight Exchange,” we explore the crucial role of Scope 3 emissions reduction in the pharmaceutical industry. Listen to L.E.K. Consulting experts Verena Ahnert and Max Cambras, who share their insights on the significance of Scope 3 emissions, the current state of commitments in pharma and how emissions reduction is both a strategic consideration and mutually beneficial to both pharma and the environment.

Key points/topics covered:

• Explanation of Scope 3 emissions and their importance in pharma

• The current state of Scope 3 commitments in the pharmaceutical industry

• Key drivers of Scope 3 emissions in pharma

• The strategic co-benefits of Scope 3 emissions reduction in the pharmaceutical industry

• The path to achieving strategic co-benefits through emissions reduction in pharma

Tune in for a deep dive into a pressing environmental issue that’s reshaping the pharma industry’s strategies and operations.

Interested in learning more? Read our Special Report, Scope 3 Emissions: A Strategic Imperative for Pharma Companies.

Connect with our experts on LinkedIn:
Verena Ahnert, Partner, L.E.K. Consulting: https://www.linkedin.com/in/verena-ahnert-7a449a2/
Max Cambras, Managing Director, L.E.K. Consulting: https://www.linkedin.com/in/max-cambras-08348411/

Visit L.E.K. Consulting at https://www.lek.com/

In this discussion, we dive into the world of brand packaging, examining the responses from a thorough survey amongst over 400 brand managers. The episode is led by the expertise of L.E.K. Consulting managing directors Thilo Henkes, Jon Moss and Jeff Cloetingh, as well as Roger Zellner, who analyze the balancing act between innovative packaging solutions and the unfolding pressures of inflation. The conversation explores the far-reaching implications of protective packaging innovation, the pivot towards sustainability in the industry, the necessity of SKU rationalisation, and the nuanced impact of packaging on consumer experiences.

Key Points/Topics Covered:

• The evolving panorama of protective packaging innovation and digital tools enhancing brand experience and supply chain efficiency.
• The delicate dance brand owners face in managing packaging, ingredients, freight, and transport costs during periods of significant inflation.
• The drive towards sustainability in packaging, with brand owners hastening investment to meet consumer expectations and industry benchmarks.
• The strategic considerations behind SKU rationalisation efforts, aimed at streamlining the supply chain and boosting profitability, yet still fostering packaging innovation.

Interested in learning more? Read our Article, Brand Owner Sentiment Points to Attractive Opportunities for Packaging.

Connect with our experts on LinkedIn:
Thilo Henkes, Managing Director, L.E.K. Consulting: https://www.linkedin.com/in/thilohenkes/
Jon Moss, Managing Director, L.E.K. Consulting: https://www.linkedin.com/in/jon-moss-a71896158/
Jeff Cloetingh, Managing Director, L.E.K. Consulting: https://www.linkedin.com/in/jeffcloetingh/
Roger Zellner, Former Director of R&D Packaging, Mondelez International (Current Advisory Board Garlock Flexibles & Industry Consultant): https://www.linkedin.com/in/rogerzellner/

Visit L.E.K. Consulting at https://www.lek.com/

Throughout this episode, our experts will discuss the intricacies of merging and acquiring businesses and the importance of the Integration Triangle, a framework we have developed to ensure successful outcomes. Host Cristina Barquero is joined by Phil Roux, a partner with 20 years of experience in M&A, and Tom Marshall, a principal in L.E.K. Consulting’s Organization and Performance practice, who share their expertise in creating sustainable value for clients and driving synergy value realization. The discussion explores the criticality of taking a pragmatic stance in mergers, the elements of the Integration Triangle, potential issues if those elements are not well integrated and best practices to follow.

Key points/topics covered:

• The critical need for a pragmatic stance in M&A to ensure value creation
• Overview of the Integration Triangle framework, encompassing value creation, the combined operating model and integration strategy
• Challenges and risks that arise when there is a lack of alignment between value creation objectives, the combined operating model and integration strategy
• Best practices for leveraging the Integration Triangle, including early planning, continuous refinement and comprehensive ownership of all three elements
• The expected outcomes of adopting an effective approach to integrating the elements of the Integration Triangle, such as increased value creation, broader buy-in and improved negotiation stance

Connect with our experts on LinkedIn:
Phil Roux, Partner, L.E.K. Consulting: https://www.linkedin.com/in/pgdroux/
Tom Marshall, Partner, L.E.K. Consulting: https://www.linkedin.com/in/tom-marshall-1078671b/
Cristina Barquero, Practice Manager (O&P), L.E.K. Consulting: https://www.linkedin.com/in/cristina-barquero3108/

Visit L.E.K. Consulting at https://www.lek.com/

In this episode, L.E.K. Consulting’s health and wellness experts discuss their survey of 1,800 consumers, which they conducted to understand evolving trends in health and wellness, and the seven distinct consumer archetypes they identified. From the traditionalist to the trendspotter, these archetypes each have a different attitude, preference and spending pattern in health and wellness. Discover how consumers are incorporating digital solutions into their wellness routines and how brands and retailers can leverage this consumer research to better understand and cater to their customer base.

Key points/topics covered:

• The shifting landscape of health and wellness, including expanded perspectives beyond just fitness and nutrition
• The seven distinct consumer archetypes identified, such as traditionalists, health enthusiasts and trendspotters
• The incorporation of digital solutions and fitness apps into health and wellness routines, and the influence of different archetypes on digital fitness content
• The surge in the use of ingestible beauty products, particularly among millennials and women
• The expansion of consumer definitions of healthy living to include recovery, good sleep habits and mental wellness, and the implications for brands and retailers in catering to different consumer archetypes

Interested in learning more? Read our Special Report, Health and Wellness: Who's Your Target Consumer?.

Connect with our L.E.K. experts on LinkedIn:
Alex Evans, Managing Director: https://www.linkedin.com/in/alexevanslek/
Geoff McQueen, Managing Director: https://www.linkedin.com/in/geoff-mcqueen/
Alison Schilling, Managing Director: https://www.linkedin.com/in/alison-schilling/
Maria Steingoltz, Managing Director: https://www.linkedin.com/in/mariasteingoltz/

Visit L.E.K. Consulting at https://www.lek.com/

In this episode, our hosts Kevin Grabenstatter, Frazer Dorey, Rozy Vig and Vance Moore discuss how the healthcare landscape is evolving, with a focus on the blurring lines between payers and providers, the entry of big box retailers and tech giants into care delivery, the growing role of private equity, and the trend of regional health system mergers. They explore the opportunities and challenges that these changes present for traditional provider organizations. This episode delves into the landscape of U.S. healthcare providers in 2035 and the implications of significant industry shifts.

Key points/topics covered:

• Blurring lines between payers and providers
• Impact of big box retailers and big tech in care delivery
• Role of private equity in healthcare delivery
• Cross-regional health system mergers
• Strategies for traditional provider organizations to adapt to industry shifts

Tune in to gain valuable insights and strategies that could shape the future of healthcare delivery.
Interested in learning more? Read our Executive Insights, Looking Ahead: The US Healthcare Provider Landscape in 2035, Part 2.

Connect with our experts on LinkedIn:
Kevin Grabenstatter, Managing Director, L.E.K. Consulting: https://www.linkedin.com/in/kgrabenstatter/
Frazer Dorey, Managing Director, L.E.K. Consulting: https://www.linkedin.com/in/frazerdorey/
Rozy Vig, Managing Director, L.E.K. Consulting: https://www.linkedin.com/in/rozyvig/
Vance Moore, a former executive at Mercy Health and current Executive in Residence at L.E.K. Consulting: https://www.linkedin.com/in/vancebmoore/

Visit L.E.K. Consulting at https://www.lek.com/

This episode delves into the complexities of transitioning to sustainable aviation fuel (SAF) and the associated costs. It addresses the potential 18% increase in airline ticket prices by 2050 and the need for market participants to efficiently access the willingness to pay for SAF. The episode also emphasises the necessity of regulatory instruments to create a level competitive playing field and the challenge of establishing consistent standards in the international aviation industry.

Key points/topics covered:

• Impact of SAF on airline ticket prices
• Market participants’ willingness to pay for SAF
• Regulatory instruments and the competitive market
• Challenges in establishing consistent standards in the international aviation industry

Join us for an in-depth conversation that paints a comprehensive picture of the future of aviation and the critical role SAF plays in it.

Interested in learning more? Read our Special Report, Fuelling the Future of Aviation.

Connect with our experts on LinkedIn:
Jack Duckworth, Partner, L.E.K. Consulting: https://www.linkedin.com/in/jack-duckworth-4178a655/
Philip Meier, Partner, L.E.K. Consulting: https://www.linkedin.com/in/philipmeierlek/
Luke Samuel, Manager, L.E.K. Consulting: https://www.linkedin.com/in/lukesamuel/

Visit L.E.K. Consulting at https://www.lek.com/